Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.75 USD | +0.27% | -1.04% | +20.21% |
16/04 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
11/04 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.21% | 703M | |
+2.93% | 108B | |
-5.24% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio's Phase 3 Trial of Imsidolimab to Treat Generalized Pustular Psoriasis Meets Primary Endpoint